Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DARA BioSciences has signed an exclusive distribution agreement with Seyer Pharmatec for Soltamox (tamoxifen citrate, oral solution) in the Commonwealth of Puerto Rico.
Subscribe to our email newsletter
The company considers launching Soltamox, the FDA-approved oral liquid formulation of tamoxifen citrate, a first-line therapy for the prevention and treatment of breast cancer, later in 2012.
DARA chief executive officer David Drutz said the exclusive agreement with Seyer Pharmatec to sell and distribute Soltamox in Puerto Rico leverages DARA’s existing commercial infrastructure, provides DARA with a well-respected and established commercial partner, and presents an opportunity to make Soltamox and potential future cancer-support products readily available for patients.
"Since DARA has exclusive rights to market Soltamox in the United States and its territories and possessions, our partnership with Seyer Pharmatec will help us maximize Soltamox sales," Drutz added.
The company believes that the availability of liquid tamoxifen offers women with breast cancer a convenient and easy-to-swallow alternative.